Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

NCT ID: NCT00492505

Last Updated: 2014-01-10

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-04-30

Brief Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as tamoxifen and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with tamoxifen and cisplatin after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying the side effects and how well giving sorafenib together with tamoxifen and cisplatin works in treating patients with high-risk stage III melanoma.

Detailed Description

OBJECTIVES:

• Compare relapse-free and overall survival of patients with high-risk stage III melanoma receiving adjuvant sorafenib tosylate, tamoxifen citrate, and cisplatin vs historical data from patients treated with tamoxifen citrate and cisplatin.
• Compare the toxicity of these regimens in these patients.

OUTLINE: This is a pilot study. Patients are stratified according to number of positive lymph nodes identified during surgery.

Patients receive oral sorafenib tosylate twice daily on days 1-28, oral tamoxifen citrate twice daily on days 1-7, and cisplatin IV over 1 hour on days 2 and 3. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically for at least 5 years.

Conditions

Melanoma (Skin)

Study Design

• Primary Study Purpose: TREATMENT

Interventions

cisplatin

Intervention Type: DRUG

sorafenib tosylate

Intervention Type: DRUG

tamoxifen citrate

Intervention Type: DRUG

adjuvant therapy

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Confirmed diagnosis of melanoma

• High-risk, stage III disease
• No measurable metastatic disease
• Has undergone surgery within the past 8 weeks

• Surgically rendered disease free

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Creatinine clearance ≥ 50 mL/min OR creatinine ≤ 1.5 mg/dL
• Liver function tests ≤ 3 times the upper limit of normal
• ANC ≥ 1,200/mm³
• Hemoglobin ≥ 9.0 g/dL
• Platelet count ≥ 100,000/mm³
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No myocardial infarction within the past 6 months
• No congestive heart failure requiring medication
• No pulmonary disease requiring supplemental oxygen
• No dyspnea at rest
• No active infection
• No chronic underlying immunodeficiency disease
• No other serious illness that, in the physicians' opinion, may compromise the safety of the patient
• No other cancer within the past 5 years except for nonmelanoma skin cancer and cervical cancer
• No thromboembolic disease within the past 6 months

PRIOR CONCURRENT THERAPY:

• No prior tamoxifen citrate, sorafenib tosylate, or cisplatin
• No concurrent radiotherapy or surgery

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

San Diego Pacific Oncology & Hematology Associates

OTHER

Sponsor Role: lead

Principal Investigators

Edward F. McClay, MD

Role: PRINCIPAL_INVESTIGATOR

San Diego Pacific Oncology & Hematology Associates

Locations

San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas

Encinitas, California, United States

Site Status: RECRUITING

Countries

United States

Facility Contacts

Edward F. McClay, MD

Role: primary

emcclay@pacificoncology.com

760-452-3340

Other Identifiers

POHA-0602

Identifier Type: -

Identifier Source: secondary_id

CDR0000551556

Identifier Type: -

Identifier Source: org_study_id